Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


England Sees Past Price Tag To Back GSK Bubble Baby Gene Therapy

Executive Summary

The cost of Strimvelis for treating severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is €594,000 but NICE has confirmed that it thinks the benefits of GSK's gene therapy, administered at a hospital in Milan, represents a fair price.

You may also be interested in...

Orchard Raises Another $150m For Gene Therapy Pot

Having recently got hold of GlaxoSmithKline's gene therapy assets, Orchard has completed another whopping financing which has got observers thinking that an IPO could soon be in the offing.

Double First At UK HTA NICE For Strimvelis, GSK’s ‘Bubble Baby’ Gene Therapy

NICE, the HTA body for England and Wales, has for the first time recommended a treatment – GSK’s gene therapy, Strimvelis – that is currently only available in another country. Also for the first time, NICE used a new system for determining the cost-effectiveness of highly specialized technologies such as this.

Spark's Luxturna Approval Ushers In A New Gene Therapy Era

Spark's gene therapy for patients with an inherited form of blindness will be available in the US late in the first quarter, but on the big question – whether it will cost $1m for the one-time treatment – Spark would not say.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts